|Bid||485.30 x 800|
|Ask||486.00 x 800|
|Day's range||472.32 - 487.45|
|52-week range||383.12 - 553.29|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||26.59|
|Earnings date||15 Jul 2022|
|Forward dividend & yield||5.80 (1.19%)|
|Ex-dividend date||11 Mar 2022|
|1y target est||568.52|
The next-generation of Align Technology's (ALGN) advanced patient communication tool will help patients see their potential new smile after Invisalign treatment.
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.